Solvonis CEO Tennyson cites patent allowance and undervaluation amid FDA feedback wait
Summary
Anthony Tennyson, CEO of Solvonis Therapeutics, stated the US Patent Office allowed broad patent claims for ketamine treatment of behavioral addictions, covering a market of 48 million Americans with protection until 2042. He cited the $1.2 billion acquisition of Transcend by Otsuka/Abbvie as a benchmark for method-of-use patents, arguing Solvonis is undervalued relative to peers like Compass Pathways and GH Research. Tennyson outlined that the company must complete a Phase 2 program to attract pharmaceutical interest, prioritizing internal capital for O01, O02, O015, and O114 programs while seeking non-dilutive financing. The company is awaiting FDA feedback on bridging O02 to Spravato and NIDA feedback on the O015 program for methamphetamine/cocaine addiction. Tennyson expects regulatory feedback and financing progress within the next 2-4 months.
Key takeaways
- 1 The US Patent Office allowed broad patent claims for ketamine treatment of behavioral addictions, covering a market of 48 million Americans with protection until 2042.
Unidentified speaker (speaker_1) · 0:22
- 2 For O01, Solvonis is adding Portuguese trial sites to gather EU citizen data for potential EU approval.
Unidentified speaker (speaker_0) · 7:26
Episode sections
- 0:18 – 1:06
Patent Allowance and Market Opportunity
The US Patent Office allowed broad patent claims for ketamine treatment of behavioral addictions, covering a market of 48 million Americans with protection until 2042. This opens commercial and licensing opportunities beyond existing addiction programs.
- 1:06 – 3:19
Commercial Strategy and Competitor Benchmarking
Anthony Tennyson states there are no licensed medications in the US for behavioral addictions like gambling or binge eating disorders. He cites the acquisition of Transcend by Otsuka/Abbvie for ~$1.2 billion as a benchmark for method-of-use patents, preferring to seek non-dilutive financing and partnerships rather than funding trials alone.
- 3:19 – 3:59
Clinical Milestones Required for Valuation
To attract pharmaceutical interest similar to Transcend, Solvonis must complete a Phase 2 program and enter Phase 3. The company is prioritizing O01, O02, O015, and O114 programs from internal capital while seeking parallel non-dilutive financing.
- 3:59 – 6:00
Market Size Comparison and Undervaluation Claim
Tennyson compares the 40 million affected by behavioral addictions to the 2-4 million with treatment-resistant depression, noting J&J's Spravato has a >$2 billion run rate. He claims Solvonis is materially undervalued compared to peers like Compass Pathways and GH Research, citing a ~£6.3m market cap.
- 6:00 – 7:26
Regulatory Feedback and Pipeline Progress
The company is awaiting FDA feedback on the bridge from O02 to Spravato and NIDA feedback on the O015 program for methamphetamine/cocaine addiction. They are also seeking non-dilutive financing for the O114 PTSD program in the US and the depression program in the UK.
- 7:26 – 10:33
European Expansion and Catalyst Timeline
For O01, Solvonis is adding Portuguese trial sites to gather EU citizen data for potential EU approval. For O02, they are working on PK/PD and TOX bridges to Spravato. Tennyson expects feedback from FDA and NIDA, and progress on O114 financing within the next 2-4 months.
- 10:33 – 12:02
O02 Asset and Behavioral Addiction Treatment Model
The O02 asset (S-ketamine oral tin film) will likely be used for behavioral addictions in combination with psychosocial support. The new patent covers racemic ketamine and its enantiomers, expanding the potential market size for O02 beyond AUD to include binge eating and gambling disorders.
- 12:02 – 12:44
Market Cap and Investor Sentiment
The host notes the company's £6.3 million market cap seems low given the pipeline. Tennyson agrees the company is undervalued relative to its assets and progress.
Claims worth verifying
The US Patent Office allowed broad patent claims covering ketamine treatment for behavioral addictions, with protection expected until 2042.
Unidentified speaker (UNKNOWN) ·0:18
How to verify: USPTO Patent Application/Public PAIR search for Solvonis Therapeutics patents allowed between Nov 2026 and Nov 2026; check patent term expiration. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Behavioral addictions affect over 48 million Americans.
Unidentified speaker (UNKNOWN) ·0:18
How to verify: NIDA or NIMH statistical reports on behavioral addictions prevalence in the US. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
There are currently no licensed medications available in the US for treating gambling disorder, pornography addiction, and binge eating disorder.
Unidentified speaker (speaker_0) ·1:26
How to verify: FDA Orange Book or EMA EMA database search for approved indications for these specific disorders. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
The patent provides exclusive use of ketamine at above 50mg dose for behavioral addictions in the US through the mid-40s.
Unidentified speaker (speaker_0) ·1:46
How to verify: Review the specific claims of the allowed US patent for Solvonis Therapeutics. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Transcend was bought by Abbi or Audsuka for ~1.2 billion.
Unidentified speaker (speaker_0) ·2:06
How to verify: SEC filings (Form 8-K) from Otsuka or AbbVie regarding the acquisition of Transcend Therapeutics. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Primary sourceTranscend had a method of use patent for methylone for PTSD and progressed to Phase 3.
Unidentified speaker (speaker_0) ·2:26
How to verify: ClinicalTrials.gov search for Transcend methylone PTSD trials; SEC filings for Transcend. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Primary sourceSolvonis is prioritizing O01, O02, O015, and O114 programs from own capital expenditure.
Unidentified speaker (speaker_0) ·3:19
How to verify: Solvonis Therapeutics annual report or interim financial statements for R&D expenditure breakdown. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Treatment resistant depression affects between 2 and 4 million Americans.
Unidentified speaker (speaker_0) ·3:59
How to verify: NIMH or NIDA statistics on Treatment Resistant Depression prevalence. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
J&J's Spravato has a run rate forecast of north of two billion.
Unidentified speaker (speaker_0) ·4:18
How to verify: Janssen/J&J earnings reports or analyst consensus estimates for Spravato sales. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Solvonis has a market cap of six point three to six point five million.
Unidentified speaker (speaker_2) ·4:52
How to verify: LSE (London Stock Exchange) listing data for SVNS on 2026-11-05. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the US Patent Office allowance for Solvonis' ketamine claims and the specific expiration date of 2042 via USPTO records.
- Confirm the acquisition price and terms of Transcend by Otsuka/Abbvie using SEC filings or press releases.
- Check the current clinical trial status and regulatory feedback timelines for Solvonis' O01, O02, O015, and O114 programs via ClinicalTrials.gov.
- Compare Solvonis' market capitalization and pipeline stage against peers Compass Pathways, GH Research, and Helius using financial data providers.
- Review J&J's Spravato sales data and patient population estimates to validate the >$2 billion run rate claim.
- Assess the company's cash runway and financing strategy by reviewing recent SEC filings for dilution risks.
- Verify the specific indications and regulatory status of behavioral addictions treatments in the US via FDA databases.
- Check for any conflicts of interest or insider trading disclosures related to the CEO's statements on undervaluation.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): Nothing in this podcast is intended as investment advice, and the people in this podcast may hold positions in the stocks they talk about. Do not buy any investment based solely on a tip or recommendation. Please do your own research.
- 0:18
- Unidentified speaker (UNKNOWN): Hello
- 0:18
- Unidentified speaker (speaker_1): and welcome back to the midweek takeaway. We welcome back Anthony Tennyson C
- 0:22
- Unidentified speaker (UNKNOWN): of
- 0:22
- Unidentified speaker (speaker_1): Solvanis Solvonis Therapeutics following news that the U.S. Patent Office has allowed broad patent claims covering ketamine treatment for behavioral addictions, a market potentially affecting over forty-eight million Americans, with protection expected until twenty forty-two. This opens up significant commercial and licensing opportunities alongside the company's
- 0:42
- Unidentified speaker (speaker_1): existing addiction treatment programmes. Welcome back, Anthony. How's life treating
- 0:46
- Unidentified speaker (UNKNOWN): you? Uh
- 0:46
- Unidentified speaker (speaker_0): Life is very good. Uh particularly pleased on the back of the the back of this morning's news.
- 0:50
- Unidentified speaker (speaker_1): Yeah, absolutely. So, yeah, as I just said there, Anthony, this patent potentially opens up a huge market beyond alcohol addiction. Just how significant is the protection across all behavioural addictions? And could we see licensing or partnership deals before Sovonis has to fund substantial clinical trials itself? Yeah,
- 1:06
- Unidentified speaker (speaker_0): great question, Phil. Thank you very much. Uh good to talk to the audience again today. So for us, yeah, this is very sick, si this is significant. This is the very large uh un significantly underserved market in the US. As you mentioned before, forty eight million people uh meet the diagnostic criteria for behavioural addictions or are affected by behavioural addictions in the US, I should say there's currently no
- 1:26
- Unidentified speaker (speaker_0): real licensed medications available in the US for treating these diseases, such as uh gambling disorder, pornography addiction and a binge eating disorder. So we will be prioritizing seeking commercial partnerships. ahead of running our own research on this in this particular field. And the reason for that is the protection is is
- 1:46
- Unidentified speaker (speaker_0): significant and the opportunity, as I mentioned before, is significant. So what the what the US Patented Office has essentially said is that we will have exclusive use of ketamine at a above 50 milligram dose, so above a disassociative dose in the US out through the mid-40s for the treatment of behavior. behavioral addictions. So that's significant. When we look at the sort of the
- 2:06
- Unidentified speaker (speaker_0): the precedence or or the commercial comparator for that, uh a company operating in our space called Transcend were recently bought by um, I believe it was either Abvi or Audsuka for in the region of 1.2 billion. And the real asset that they had was a method of use patent for methylone, which is a well understood patent, well well-understood understood molecule, much like
- 2:26
- Unidentified speaker (speaker_0): ketamine. is a well understood molecule. They had exclusive use of that under patent for the treatment of post traumatic stress disorder. And they progressed that asset through phase two and into phase three. So it was worth obviously a material amount in a transaction. My preference right now is to do two things is to seek non dilutive financing in the UK pay primarily and
- 2:46
- Unidentified speaker (speaker_0): in the US to progress a clinical stage research at low no cost to the company. and in parallel with that to seek commercial partnerships in the US to either progress that research together jointly in the US or to outlicense the asset um fully or by indication in the US.
- 3:02
- Unidentified speaker (speaker_1): Yeah, absolutely. Yeah I was I was just going to reference that the the OSCAS um acquisition of Transcend for I think it was seven hundred million dollars up front and then an additional five hundred and twenty twenty-five five million dollars in sales related payments. But you know what does Solvanis need to demonstrate clinically to attract similar pharmaceutical interest, do you think?
- 3:19
- Unidentified speaker (speaker_0): We would need to complete a phase two program and be in phase three to do to be at exactly the same stage as Transcend was when they outlicensed or sold on uh the company. So we are prioritizing our O one, O two, O one five, and one one four programs from our own capital expenditure. So what we will be doing is we'll be see we will it be we'll
- 3:39
- Unidentified speaker (speaker_0): see, as I said before, we'll be doing two things parallel path, seeking non-dilutive financing in the UK and the US to progress clinical stage research forward, primarily targeting b uh gambling disorder and binge eating disorder, and in parallel with that seeking immediate commercial partnerships or commercial opportunities for these assets.
- 3:55
- Unidentified speaker (speaker_2): Very good. I mean, this is a significant step, uh I'm saying.
- 3:59
- Unidentified speaker (speaker_0): Yeah, it's it it is a significant step. It's a granting of a method of use patent in the large largest pharmaceutical market in the world for a indication class that affects fourteen million Americans. Uh to put that in context, treatment resistant depression affects between two, two and four million Americans. And the comparative drug that I always reference for our O two programme, J and
- 4:18
- Unidentified speaker (speaker_0): J's bravato, has a run rate forecast of north of two billion for an indication that just affects two to four million people. So this if there are 40 million Americans affected by behavioral addictions. Ketamine is a well understood and safe drug as far medicine as far as the regulator is concerned. And we now have patent protection or
- 4:39
- Unidentified speaker (speaker_0): a patent allowed to be granted in Q1 of next year for the use of that well understood and accepted as safe medicine by the regulators in the US for the treatment of an of a range of indications that affect north more to 40 than million. forty million Americans. That is significant.
- 4:52
- Unidentified speaker (speaker_2): So at six point three to six point five million market cap as we speak in Sylvanas, um yeah, I d I don't really even know how to ask the question. It's like surely with these patents, with the the stuff that you're working on in terms of zero zero one, zero zero two, zero one five, you know, you are massively
- 5:12
- Unidentified speaker (speaker_2): undervalued now now that this patent paint has come in.
- 5:15
- Unidentified speaker (speaker_0): I would agree. You look at our peer companies in the US and the psychedelics and psychedelic adjacent space, they are defininium market cap is several billion. Compass pathways, GH research, HELUS, we are materially undervalued compared to them. Yes, they are slightly more progressed than us, but by a number of years,
- 5:35
- Unidentified speaker (speaker_0): not by a number of decades. And their order their evaluation valuation is an order of maximum magnitude higher than ours. So what we will continue to do is we will continue to execute the strategy. We'll continue to progress 001 through the phase three. We are continue to discuss with our commercial partners, or we continue to discuss with our partners on that trial, University of Exeter
- 5:55
- Unidentified speaker (speaker_0): and particularly NIHOR, in how we can expand that trial into Europe.
- 6:00
- Unidentified speaker (speaker_0): We continue to progress 002. OO2. We are awaiting feedback, as I think I've mentioned before, we're awaiting feedback from the FDA from our tight D meeting request, and that should be coming in imminently.
- 6:11
- Unidentified speaker (speaker_0): On the scope of the remaining program to bridge from our OO2 asset into the reference product sprovato, that's a blockbuster drug. We are also awaiting waiting feedback from NIDA on the next stage of work, or the progress to date and then next stage of work for a fully federal US government currently funded programme for methamphetamine and cocaine addiction.
- 6:31
- Unidentified speaker (speaker_0): And we are seeking non dilutive financing in the US to progress the PTSD programme forward one one four, non dilutive financing in the UK to progress the depression programme forward. And now we have this additional asset. So yeah, I'd say we're undervalued given the amount of activity and progress and potential we have.
- 6:47
- Unidentified speaker (speaker_2): Very good. Um where do you see the next catalyst coming from? Do you think uh obviously we we've we've got the um the pavements now. We're look we're looking at um the FDA situation coming in very shortly as well. Obviously the spravato thing in terms of uh taking that bridge is gonna be a a
- 7:07
- Unidentified speaker (speaker_2): huge leap, I think, 'cause 'Cause it's gonna going save to you a lot of uh a lot of work and a lot of um cost as well, I presume. So what is is that where we see the next things coming, or are you gonna bring something out of the blue that will will fund some things? Obviously, which you're not gonna tell us, but we will try and ask anyway.
- 7:26
- Unidentified speaker (speaker_0): Great question. Thanks, Kevin. Um so we have a we have a rich body of catalysts uh coming down the track. Uh for O01, our core priority is to expand that programme, program, uh that trial, I should say, into the European into Europe or into the European Union. by adding Portuguese trial sites to the trial. Reason for that is we want EU citizen data in the trial pool
- 7:46
- Unidentified speaker (speaker_0): to increase in our opinion the probability of s of a successful approval in selected EU economies in due course. As I said earlier on in the call or the the the chat, we are we continue our commercial discussions with our partners on that trial. They are commercial so I can't talk about them but as soon as we have progress made and everyone is in agreement, we will be making
- 8:06
- Unidentified speaker (speaker_0): announcements. For OO2, we're working to continue to establish the bridge between our S ketamine oral tinfilm and JJ's S ketamine nasal spray, as has been requested by the FDA. That was across PKPD and then TOX. So we're awaiting feedback from the FDA on and the scope of our TOX talks package, which we have reduced because of the positive data we
- 8:26
- Unidentified speaker (speaker_0): identified. we or created in the PKPD section. And that is all part of our program and our plan to be able to secure approval from the FDA to go straight into a phase two B program in the US for moderate to severe AUD in due course. And then for the preclinical de novo program 015, we're awaiting feedback from the from NIDA on progress to date
- 8:46
- Unidentified speaker (speaker_0): on the remaining work, and on sorry, some of the remaining work for 114. we are in the process of seeking non-dilutive financing in the US to progress 114 forward for PTSD. And then 015 is a dual use asset, so for both methamphetamine, but also we believe is a potential third generation antidepressant. So we're seeking non-dilutive
- 9:06
- Unidentified speaker (speaker_0): financing in the UK to progress that forward. And you layer now on top of that today's news, where we have a very interesting asset with exclusive use in a very large commercially attractive market for k ketamine for behavioral addictions in the US, where we're now going to seek immediate commercial partnerships and non diluted financing to progress that forward. So we have a
- 9:25
- Unidentified speaker (speaker_0): large lot of activity ongoing and some good news flow to come out over the next months.
- 9:30
- Unidentified speaker (speaker_2): Yeah, I mean that that was my next question, even though we hate to tie these things down to time, but in the next say two to four months, what do you expect to uh to actually arrive?
- 9:40
- Unidentified speaker (speaker_0): Progress on 002, feedback from FDA on O. Sorry, I begress on O01, feedback from FDA on O02 and agreed next steps on O02, feedback from NIDA on progress for 015 and next steps for 015, and ideally progress on 114 one one four with regard to non none the
- 10:00
- Unidentified speaker (speaker_0): submission, not the winning, but the submission or at least a plan in the US to progress one one four forward. That is what I have confidence over in the next two to four months. Other things are ongoing as well.
- 10:10
- Unidentified speaker (speaker_2): Very good. The the thing that was interesting that you said about the gambling and eating disorders in the US because of the ketamine, because we we basically haven't touched on these before. Um how how do you see that progressing? Is it going to be similar to zero zero one where you take the ketamine? and then there is some sort of uh counseling or
- 10:30
- Unidentified speaker (speaker_2): advice uh system set up? I I don't know what the
- 10:33
- Unidentified speaker (speaker_0): I think it would probably be closer to what we're thinking of for OO2. So it would be S ketamine in the oral tin film. We would use that asset. We have exclusive use of that asset globally from LTS Lohman in um in addiction, anxiety, PTSD, and eating disorders. So that it there's a better IP profile around that given. the fact that LTS Lohmann have granted
- 10:53
- Unidentified speaker (speaker_0): formulation patents filed for that oral tin film, and now we have method of use patents allowed in the US. And it's important that that method of use patent that's been allowed today covers rhythmic ketamine and the two enantomers of S and R. So it would most likely be a course of S-ketamine, oral tin
- 11:13
- Unidentified speaker (speaker_0): tinfilm, film, in combination with I. either in clinic psychosocial support or digital psychosocial support. We'll just need to work that out.
- 11:21
- Unidentified speaker (UNKNOWN): Yeah,
- 11:21
- Unidentified speaker (speaker_2): because this more than doubles your uh potential market size, no?
- 11:25
- Unidentified speaker (speaker_0): Mm more than doubles the market size for OO two.
- 11:28
- Unidentified speaker (speaker_2): Well, just in general, that you're gonna be using the the both patents that have been granted now, your O OO two and then moving into other things such as the gambling
- 11:37
- Unidentified speaker (UNKNOWN): and
- 11:38
- Unidentified speaker (speaker_2): all of a sudden you know, we're we're casting a very wide net as opposed to this is what we're after.
- 11:44
- Unidentified speaker (speaker_0): Correct. Um but bear in mind, moderate to severe AUD in the US affects eleven million people, right? Um binge disorder now affects you know sever several more million people, as does gambling disorder. So this significantly increases the interest and the value to us and potentially to future partners of the O OO2 two asset.
- 12:02
- Unidentified speaker (speaker_2): Okay, very good. Well, we look forward to future news, Anthony. I mean, don't think there's much else to say. I mean, six point three million pounds for a biotech uh company with this many uh irons in the fire seems absolutely bizarre, but there you go. Such is life at the minute.
- 12:17
- Unidentified speaker (speaker_0): Indeed. Thank you very much for your time. Really appreciate it. Yeah,
- 12:20
- Unidentified speaker (speaker_1): Anthony Tennyson, CEO of Solvon Solvonis is therapeutics. Thanks very much for appearing on the podcast.
- 12:25
- Unidentified speaker (speaker_3): This podcast was brought to you by Roast PR Limited. If you would like to appear on a future episode of The Sunday Roast, please email admin at thesundayroast.net.
More from The Sunday Roast
S12 Ep20: Midweek Takeaway with Sapan Ghai, Chief Commercial Officer of Sovereign Metals Limited (AIM:SVML) #SVML
Episode discussion: Sapan Ghai discusses Sovereign Metals' Kasiya project, DFS results, and dividend potential with Tim Carstens
Speakers’ claims: Sapan Ghai, Chief Commercial Officer of Sovereign Metals (SVML), outlines the company's Kasiya Critical Minerals Project in Malawi, which hosts the world's largest rutile and second-largest graphite deposits. He highlights the completion of a Definitive Feasibility Study (DFS) in April 2026 and the appointment of Executive Chairman Tim Carstens, citing his track record at Base Resources. Ghai emphasizes the price bifurcation for non-Chinese supply chains, noting extreme premiums for materials like yttrium. The discussion projects significant free cash flow and potential dividends that could cover the market cap within two to three years.
S12 Ep18: Sunday Roast featuring Delta Gold Technologies, Ajax Resources plc, Fulcrum Metals and Aterian PLC #DGQ #AJAX #FMET #ATN #TGR
Episode discussion: Sunday Roast S12 Ep18: Delta Gold, Ajax Resources, Fulcrum Metals, Aterian PLC, and Total Graphite
Speakers’ claims: Hosts and guests discuss market reactions to US midterm elections and detail corporate updates for five mining and technology firms. Delta Gold Technologies outlines its quantum sensing expansion and government engagement. Ajax Resources describes its Paguanta acquisition, Norwegian listing, and strategic pivot to revenue generation. Fulcrum Metals reports on pilot plant progress and uranium asset optioning. Aterian PLC highlights record tantalum sales and trading margins. Total Graphite discusses a Tanzanian acquisition and fundraise.